Heritage Wealth Management Inc. Lowers Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Heritage Wealth Management Inc. lessened its stake in Bristol-Myers Squibb (NYSE:BMY) by 7.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 8,583 shares of the biopharmaceutical company’s stock after selling 725 shares during the period. Heritage Wealth Management Inc.’s holdings in Bristol-Myers Squibb were worth $444,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Csenge Advisory Group boosted its stake in shares of Bristol-Myers Squibb by 12.0% in the first quarter. Csenge Advisory Group now owns 9,484 shares of the biopharmaceutical company’s stock valued at $514,000 after purchasing an additional 1,018 shares during the period. CFO4Life Group LLC acquired a new stake in Bristol-Myers Squibb during the 1st quarter worth approximately $233,000. Envestnet Portfolio Solutions Inc. boosted its position in Bristol-Myers Squibb by 35.6% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 187,968 shares of the biopharmaceutical company’s stock valued at $10,194,000 after buying an additional 49,342 shares during the period. Hilltop National Bank acquired a new position in shares of Bristol-Myers Squibb in the first quarter worth $436,000. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of Bristol-Myers Squibb by 4.7% in the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 14,492 shares of the biopharmaceutical company’s stock valued at $786,000 after acquiring an additional 654 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,830 shares of the company’s stock in a transaction on Friday, November 1st. The shares were bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the transaction, the executive vice president now owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Samit Hirawat purchased 1,830 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the acquisition, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of BMY traded down $0.49 during mid-day trading on Friday, reaching $54.22. 302,516 shares of the company’s stock were exchanged, compared to its average volume of 14,354,405. The business’s fifty day simple moving average is $51.69 and its 200-day simple moving average is $46.72. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $56.80. The stock has a market capitalization of $109.97 billion, a PE ratio of -15.25, a price-to-earnings-growth ratio of 12.39 and a beta of 0.44. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. During the same period in the previous year, the business posted $2.00 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 8.4% on a year-over-year basis. On average, equities research analysts expect that Bristol-Myers Squibb will post 0.9 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.43%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -66.85%.

Analyst Ratings Changes

BMY has been the topic of a number of analyst reports. UBS Group increased their price target on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, October 9th. TD Cowen boosted their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Sanford C. Bernstein started coverage on shares of Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 price objective on the stock. BMO Capital Markets increased their target price on Bristol-Myers Squibb from $53.00 to $57.00 and gave the company a “market perform” rating in a report on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $53.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.